Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
52
MEDIF Quote, Financials, Valuation and Earnings
Last price:
$0.05
Seasonality move
:
18.17%
Day range:
$0.05 - $0.05
52-week range:
$0.04 - $0.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.69x
P/B ratio:
0.84x
Volume:
107.9K
Avg. volume:
145.4K
1-year change:
12.42%
Market cap:
$22.8M
Revenue:
$30.6M
EPS (TTM):
-$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs Corp.
|
$8.4M | -- | -2.19% | -- | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 24.77% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.06 | -- | -10.97% | $5.50 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.20 | -100% | -36.71% | $55.51 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs Corp.
|
$0.05 | -- | $22.8M | -- | $0.00 | 0% | 0.69x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$15.15 | $16.67 | $2B | 27.00x | $0.00 | 0% | 8.04x |
|
EDSA
Edesa Biotech, Inc.
|
$1.50 | $11.00 | $10.5M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.75 | $4.50 | $18.6M | -- | $0.00 | 0% | 19.03x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.97 | $5.50 | $104.1M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$42.15 | $55.51 | $3.3B | -- | $0.00 | 0% | 442.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MEDIF
MediPharm Labs Corp.
|
1.11% | -3.141 | 1.27% | 1.97x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.204 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -1.109 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -0.522 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.553 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | -0.090 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MEDIF
MediPharm Labs Corp.
|
$1.8M | -$1.6M | -19.11% | -19.3% | -18.68% | -$112.2K |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
MediPharm Labs Corp. vs. Competitors
-
Which has Higher Returns MEDIF or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of 42.95%. MediPharm Labs Corp.'s return on equity of -19.3% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs Corp.21.17% -$0.00 $27.5M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About MEDIF or AUPH?
MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 10.01%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than MediPharm Labs Corp..
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs Corp.0 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is MEDIF or AUPH More Risky?
MediPharm Labs Corp. has a beta of 0.504, which suggesting that the stock is 49.609% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.187%.
-
Which is a Better Dividend Stock MEDIF or AUPH?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or AUPH?
MediPharm Labs Corp. quarterly revenues are $8.3M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. MediPharm Labs Corp.'s net income of -$1.6M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 8.04x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs Corp.0.69x -- $8.3M -$1.6M AUPHAurinia Pharmaceuticals, Inc.8.04x 27.00x $73.5M $31.6M
-
Which has Higher Returns MEDIF or EDSA?
Edesa Biotech, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of --. MediPharm Labs Corp.'s return on equity of -19.3% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs Corp.21.17% -$0.00 $27.5M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About MEDIF or EDSA?
MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 633.33%. Given that Edesa Biotech, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Edesa Biotech, Inc. is more attractive than MediPharm Labs Corp..
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs Corp.0 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is MEDIF or EDSA More Risky?
MediPharm Labs Corp. has a beta of 0.504, which suggesting that the stock is 49.609% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.133, suggesting its less volatile than the S&P 500 by 86.677%.
-
Which is a Better Dividend Stock MEDIF or EDSA?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or EDSA?
MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$1.6M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs Corp.0.69x -- $8.3M -$1.6M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns MEDIF or LEXX?
Lexaria Bioscience Corp. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of -2178.51%. MediPharm Labs Corp.'s return on equity of -19.3% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs Corp.21.17% -$0.00 $27.5M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About MEDIF or LEXX?
MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 503.22%. Given that Lexaria Bioscience Corp. has higher upside potential than MediPharm Labs Corp., analysts believe Lexaria Bioscience Corp. is more attractive than MediPharm Labs Corp..
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs Corp.0 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is MEDIF or LEXX More Risky?
MediPharm Labs Corp. has a beta of 0.504, which suggesting that the stock is 49.609% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.631, suggesting its less volatile than the S&P 500 by 36.888%.
-
Which is a Better Dividend Stock MEDIF or LEXX?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or LEXX?
MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. MediPharm Labs Corp.'s net income of -$1.6M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 19.03x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs Corp.0.69x -- $8.3M -$1.6M LEXXLexaria Bioscience Corp.19.03x -- $174K -$2.7M
-
Which has Higher Returns MEDIF or ONCY?
Oncolytics Biotech, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of --. MediPharm Labs Corp.'s return on equity of -19.3% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs Corp.21.17% -$0.00 $27.5M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About MEDIF or ONCY?
MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 470.11%. Given that Oncolytics Biotech, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Oncolytics Biotech, Inc. is more attractive than MediPharm Labs Corp..
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs Corp.0 0 0 ONCYOncolytics Biotech, Inc.4 1 0 -
Is MEDIF or ONCY More Risky?
MediPharm Labs Corp. has a beta of 0.504, which suggesting that the stock is 49.609% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.717%.
-
Which is a Better Dividend Stock MEDIF or ONCY?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or ONCY?
MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$1.6M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs Corp.0.69x -- $8.3M -$1.6M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns MEDIF or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of -867.29%. MediPharm Labs Corp.'s return on equity of -19.3% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital MEDIFMediPharm Labs Corp.21.17% -$0.00 $27.5M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About MEDIF or XENE?
MediPharm Labs Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.51 which suggests that it could grow by 31.69%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than MediPharm Labs Corp..
Company Buy Ratings Hold Ratings Sell Ratings MEDIFMediPharm Labs Corp.0 0 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is MEDIF or XENE More Risky?
MediPharm Labs Corp. has a beta of 0.504, which suggesting that the stock is 49.609% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 0.974, suggesting its less volatile than the S&P 500 by 2.579%.
-
Which is a Better Dividend Stock MEDIF or XENE?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MEDIF or XENE?
MediPharm Labs Corp. quarterly revenues are $8.3M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$1.6M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.69x versus 442.96x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MEDIFMediPharm Labs Corp.0.69x -- $8.3M -$1.6M XENEXenon Pharmaceuticals, Inc.442.96x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
